BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Rating) have been assigned a consensus recommendation of “Buy” from the seven research firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $76.43.

A number of analysts have commented on BTAI shares. Canaccord Genuity Group cut their price target on shares of BioXcel Therapeutics from $95.00 to $81.00 in a research report on Friday, March 11th. Bank of America upped their price target on shares of BioXcel Therapeutics from $78.00 to $80.00 and gave the company a “buy” rating in a research report on Wednesday, April 6th. UBS Group cut their price target on shares of BioXcel Therapeutics from $88.00 to $25.00 and set a “buy” rating on the stock in a research report on Wednesday, February 16th. Finally, HC Wainwright cut their price target on shares of BioXcel Therapeutics from $140.00 to $130.00 and set a “buy” rating on the stock in a research report on Monday, March 14th.

Several hedge funds and other institutional investors have recently made changes to their positions in BTAI. AlphaCentric Advisors LLC acquired a new position in BioXcel Therapeutics during the 4th quarter valued at about $1,017,000. Barclays PLC lifted its holdings in shares of BioXcel Therapeutics by 102.4% in the fourth quarter. Barclays PLC now owns 20,929 shares of the company’s stock valued at $426,000 after purchasing an additional 10,588 shares in the last quarter. BlackRock Inc. boosted its position in shares of BioXcel Therapeutics by 6.0% during the fourth quarter. BlackRock Inc. now owns 1,289,654 shares of the company’s stock valued at $26,218,000 after buying an additional 72,917 shares during the last quarter. Wells Fargo & Company MN grew its holdings in BioXcel Therapeutics by 100.8% during the fourth quarter. Wells Fargo & Company MN now owns 19,704 shares of the company’s stock worth $400,000 after buying an additional 9,889 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its position in BioXcel Therapeutics by 38.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 49,734 shares of the company’s stock valued at $1,011,000 after buying an additional 13,765 shares during the last quarter. Hedge funds and other institutional investors own 45.69% of the company’s stock.

Shares of BioXcel Therapeutics stock traded down $0.30 during trading on Thursday, hitting $15.98. The company’s stock had a trading volume of 23,207 shares, compared to its average volume of 1,358,821. BioXcel Therapeutics has a 52 week low of $14.32 and a 52 week high of $39.00. The stock has a 50-day moving average price of $18.02 and a two-hundred day moving average price of $22.51.

BioXcel Therapeutics (NASDAQ:BTAI – Get Rating) last issued its quarterly earnings results on Thursday, March 10th. The company reported ($0.93) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.18) by $0.25. During the same quarter in the prior year, the firm posted ($0.87) EPS. As a group, equities analysts anticipate that BioXcel Therapeutics will post -4.71 earnings per share for the current fiscal year.

BioXcel Therapeutics Company Profile (Get Rating)

BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors.

Featured Articles